Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals
Conclusion In this interferon-free era, PegIFN-based regimens remain a safe and effective option for selected HCV patients.
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Databases & Libraries | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Liver Cancer | Norvir | Pancreas | Pancreatic Cancer | Pegasys | Study | Virology